Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 851

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

Breast-Cancer Risk in Families with Mutations in PALB2

Open access
Antoniou, Antonis C., Casadei, Silvia, Heikkinen, Tuomas, Barrowdale, Daniel, Pylkäs, Katri, Roberts, Jonathan, Lee, Andrew, Subramanian, Deepak, De Leeneer, Kim, Fostira, Florentia, Tomiak, Eva, Neuhausen, Susan L., Teo, Zhi L., Khan, Sofia, Aittomäki, Kristiina, Moilanen, Jukka S., Turnbull, Clare, Seal, Sheila, Mannermaa, Arto, Kallioniemi, Anne, Lindeman, Geoffrey J., Buys, Saundra S., Andrulis, Irene L., Radice, Paolo, Tondini, Carlo, Manoukian, Siranoush, Toland, Amanda E., Miron, Penelope, Weitzel, Jeffrey N., Domchek, Susan M., Poppe, Bruce, Claes, Kathleen B.M., Yannoukakos, Drakoulis, Concannon, Patrick, Bernstein, Jonine L., James, Paul A., Easton, Douglas F., Goldgar, David E., Hopper, John L., Rahman, Nazneen, Peterlongo, Paolo, Nevanlinna, Heli, King, Mary-Claire, Couch, Fergus J., Southey, Melissa C., Winqvist, Robert, Foulkes, William D., Tischkowitz, Marc·2014·New England Journal of Medicine

Abstract

BACKGROUND: Germline loss-of-function mutations in PALB2 are known to confer a predisposition to breast cancer. However, the lifetime risk of breast cancer that is conferred by such mutations remains unknown. METHODS: We analyzed the risk of breast cancer among 362 members of 154 families who had deleterious truncating, splice, or deletion mutations in PALB2. The age-specific breast-cancer risk for mutation carriers was estimated with the use of a modified segregation-analysis approach that allowed for the effects of PALB2 genotype and residual familial aggregation. RESULTS: The risk of breast cancer for female PALB2 mutation carriers, as compared with the general population, was eight to nine times as high among those younger than 40 years of age, six to eight times as high among those 40 to 60 years of age, and five times as high among those older than 60 years of age. The estimated cumulative risk of breast cancer among female mutation carriers was 14% (95% confidence interval [CI], 9 to 20) by 50 years of age and 35% (95% CI, 26 to 46) by 70 years of age. Breast-cancer risk was also significantly influenced by birth cohort (P<0.001) and by other familial factors (P=0.04). The absolute breast-cancer risk for PALB2 female mutation carriers by 70 years of age ranged from 33% (95% CI, 25 to 44) for those with no family history of breast cancer to 58% (95% CI, 50 to 66) for those with two or more first-degree relatives with breast cancer at 50 years of age. CONCLUSIONS: Loss-of-function mutations in PALB2 are an important cause of hereditary breast cancer, with respect both to the frequency of cancer-predisposing mutations and to the risk associated with them. Our data suggest the breast-cancer risk for PALB2 mutation carriers may overlap with that for BRCA2 mutation carriers. (Funded by the European Research Council and others.).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa1400382

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 36 references

Cited by

See all 851

Metadata

Authors
Antoniou, A. C., Casadei, S., Heikkinen, T., Barrowdale, D., Pylkäs, K., Roberts, J., Lee, A., Subramanian, D., De Leeneer, K., Fostira, F., Tomiak, E., Neuhausen, S. L., Teo, Z. L., Khan, S., Aittomäki, K., Moilanen, J. S., Turnbull, C., Seal, S., Mannermaa, A., Kallioniemi, A., Lindeman, G. J., Buys, S. S., Andrulis, I. L., Radice, P., Tondini, C., Manoukian, S., Toland, A. E., Miron, P., Weitzel, J. N., Domchek, S. M., Poppe, B., Claes, K. B. M., Yannoukakos, D., Concannon, P., Bernstein, J. L., James, P. A., Easton, D. F., Goldgar, D. E., Hopper, J. L., Rahman, N., Peterlongo, P., Nevanlinna, H., King, M.-C., Couch, F. J., Southey, M. C., Winqvist, R., Foulkes, W. D., & Tischkowitz, M.
Venue
New England Journal of Medicine
Published
2014-08-07
Volume
371
Issue
6
Pages
497-506
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2194014097
Cited by
851
References
36
FWCI
57.85
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Breast-Cancer Risk in Families with Mutations in PALB2. https://app.cochat.ai/papers/10.1056/nejmoa1400382
The paper
Antoniou, A. C., Casadei, S., Heikkinen, T., Barrowdale, D., Pylkäs, K., Roberts, J., Lee, A., Subramanian, D., De Leeneer, K., Fostira, F., Tomiak, E., Neuhausen, S. L., Teo, Z. L., Khan, S., Aittomäki, K., Moilanen, J. S., Turnbull, C., Seal, S., Mannermaa, A., . . . Tischkowitz, M. (2014). Breast-Cancer Risk in Families with Mutations in PALB2. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1400382

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.